In 2018, Hutchmed’s fruquintinib became the first domestically developed drug for a major cancer type to be approved in China. Five years later, the FDA has ... which will allow you to be ...
IceCure filed the De Novo request with the FDA in ... breast cancer in numerous countries, including in the European Union, Brazil, and China. "We believe the appeal process allows us to work ...
The U.S. Food and Drug Administration is screening imports of cinnamon from multiple ... more than 200 times higher than proposed FDA guidance would allow, officials said. The agency does not ...
In 2008, adulterated chemicals from a manufacturing plant for the blood-thinner heparin in China led to 81 deaths in the U.S. Ten years later, a cancer causing ... of shortages of the drug were ...
A recent development in the pharmaceutical industry has highlighted a significant disparity in drug pricing between the United States and China. A cancer drug, developed by Chinese scientists and ...
In China, a single-dose vial costs US$280 but in the US it will have a wholesale price of US$8,892 Following the approval by ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved AstraZeneca's Truqap in combination with an older drug, providing another treatment option for patients with the most common type ...
The FDA said on Wednesday that the approval allows the use of the drug to treat patients with ROS1-positive non-small cell lung cancer (NSCLC), which occurs when the ROS1 gene fuses with another ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved AstraZeneca's Truqap in combination with an older drug, providing another treatment option for patients with the most common ...
The FDA decision allows use of the drug, chemically known as capivasertib, in combination with the British drugmaker's older cancer treatment faslodex. The Truqap combination enters a competitive ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved AstraZeneca's Truqap in combination with an older drug, providing another treatment option for patients with the most common ...
The FDA said on Wednesday that the approval allows the use of the drug to treat patients with ROS1-positive non-small cell lung cancer (NSCLC), which occurs when the ROS1 gene fuses with another ...
